图书馆订阅: Guest
肿瘤形成评论综述™

每年出版 4 

ISSN 打印: 0893-9675

ISSN 在线: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Role of the Progesterone Receptor (PR) and the PR Isoforms in Breast Cancer

卷 13, 册 4, 2007, pp. 283-302
DOI: 10.1615/CritRevOncog.v13.i4.20
Get accessGet access

摘要

Known risk factors for breast cancer include overexposure to exogenous or endogenous hormones, namely, estrogen and progesterone. The effects of progesterone acts via two isoforms of the progesterone receptor (PR) termed A (PRA) and B (PRB). There is a single human PR gene with two distinct promoter regions in exon 1 encoding the two isoforms. Studies have shown that in poor prognostic tumors, the ratio between PRA and PRB is altered, with a predominance of PRA and loss of PRB. PRA and PRB regulate different subsets of genes involved in particular functional pathways. Breast tumors that express PR are associated with slow growth, better differentiation, and better overall prognosis in the short term. Both estrogen receptor alpha (ERα) and total progesterone receptor (PR) are immunohistochemically measured on breast cancer specimens to help determine those patients who would benefit from hormonal treatment. Depending on the hormone receptor status and the menopausal status of the patient, different treatments are available. Although the value of ERα in predicting response to hormone therapy in early breast cancer patients is undisputed, the value of PR is currently under debate. Historically, PR was thought to be a surrogate marker for ER expression; however, it is now known that lack of PR expression can indicate underlying epidermal growth factor receptor signaling or promoter methylation. This has implications for and can dictate hormone therapy responsiveness. Further studies investigating the specific isoforms and their pathways will help to reveal the underlying mechanisms of PR-induced breast tumori-genesis and help in assigning the most appropriate patient-tailored treatment.

对本文的引用
  1. Gupta Akash, Mehta Rajeshwari, Alimirah Fatouma, Peng Xinjian, Murillo Genoveva, Wiehle Ronald, Mehta Rajendra G., Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells, The Journal of Steroid Biochemistry and Molecular Biology, 133, 2013. Crossref

  2. Yang Li-Heng, Tseng Hsin-Shun, Lin Che, Chen Li-Sheng, Chen Shou-Tung, Kuo Shou-Jen, Chen Dar-Ren, Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients, Journal of Breast Cancer, 15, 3, 2012. Crossref

  3. Medina-Jaime Alma Delia, Reyes-Vargas Francianella, Martinez-Gaytan Victoria, Zambrano-Galvan Graciela, Portillo-DelCampo Eduardo, Burciaga-Nava Jorge Alberto, Reyes-Romero Miguel, Sifuentes-Alvarez Antonio, ESR1 and PGR Gene Promoter Methylation and Correlations with Estrogen and Progesterone Receptors in Ductal and Lobular Breast Cancer, Asian Pacific Journal of Cancer Prevention, 15, 7, 2014. Crossref

  4. Abderrahman Balkees, Jordan V. Craig, Steroid Receptors in Breast Cancer, in The Breast, 2018. Crossref

  5. Guil-Luna S., Stenvang J., Brünner N., Sánchez-Céspedes R., Millán Y., Gómez-Laguna J., Mulas J. Martín de las, Progesterone Receptor Isoform Analysis by Quantitative Real-Time Polymerase Chain Reaction in Formalin-Fixed, Paraffin-Embedded Canine Mammary Dysplasias and Tumors, Veterinary Pathology, 51, 5, 2014. Crossref

  6. Kabel Ahmed M., Tumor markers of breast cancer: New prospectives, Journal of Oncological Sciences, 3, 1, 2017. Crossref

  7. Losada-Echeberría María, Herranz-López María, Micol Vicente, Barrajón-Catalán Enrique, Polyphenols as Promising Drugs against Main Breast Cancer Signatures, Antioxidants, 6, 4, 2017. Crossref

  8. Calhoun Benjamin C., Mosteller Brian, Warren Daniel, Smith Margie, Jordi Rowe J., Lanigan Christopher P., Mrazeck Karen C., Walker Espen, Newell Amy Hanlon, Jones Raymond, Analytical and clinical performance of progesterone receptor antibodies in breast cancer, Annals of Diagnostic Pathology, 35, 2018. Crossref

  9. Arnott John A., Sonia Lobo , Hormones of Programmed Cell Death, in Hormonal Signaling in Biology and Medicine, 2020. Crossref

  10. Jeong Seri, Park Min-Jeong, Song Wonkeun, Kim Hyon-Suk, Current immunoassay methods and their applications to clinically used biomarkers of breast cancer, Clinical Biochemistry, 78, 2020. Crossref

  11. Pu Huijie, Wen Xiaosha, Luo DiXian, Guo Zifen, Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system, The Journal of Steroid Biochemistry and Molecular Biology, 2022. Crossref

  12. Davodabadi Fatemeh, Sarhadi Mohammad, Arabpour Javad, Sargazi Saman, Rahdar Abbas, Díez-Pascual Ana M., Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches, Journal of Controlled Release, 349, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain